Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
From Promise to Therapy
Join The Seattle Genetics Team
We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.
FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma More
Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb More
Seattle Genetics Reports Second Quarter 2017 Financial Results More
Seattle Genetics At A Glance
|Global Headquarters||Bothell, WA|
|Number of Employees||1,000+|
|Clinical & preclinical pipeline programs||12+|
|ADCs in clinical trials using our technology||20+|
FDA PDUFA action date is December 16, 2017 and we look forward to working with the FDA to secure approval for CTCL · 1 day ago
Good luck to our @Obliteride riders and thank you to our volunteers! Here’s to a beautiful weekend cycling for a faster cure. · 6 days ago